June 29, 2020 / 11:49 AM / 11 days ago

BRIEF-Rocket Pharmaceuticals Announces FDA Clearance Of Ind For Rp-L401 Gene Therapy For Infantile Malignant Osteopetrosis

June 29 (Reuters) - Rocket Pharmaceuticals Inc:

* ROCKET PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR RP-L401 GENE THERAPY FOR INFANTILE MALIGNANT OSTEOPETROSIS

* ROCKET PHARMACEUTICALS- CO’S FIFTH GENE THERAPY PROGRAM TO ENTER CLINIC IN Q4 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below